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Abstract: The systemic vasculitides are a group of multisystem diseases, which can be life 
and organ threatening. High-dose immunosuppressants are required to control inflammation in 
vital organs, such as the kidneys, lungs, skin, joints, and eyes. Patients report a range of impacts 
on their health-related quality of life due to symptoms, irreversible damage, and the adverse 
effects of medications. The measurement of patient perspectives within clinical studies in vas-
culitis is essential to capture outcomes of greatest importance to patients. Validated generic, 
disease-specific and symptom-specific patient-reported outcomes available for use in patients 
with systemic vasculitis are reviewed here.
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Introduction
The systemic vasculitides present clinically with inflammation in multiple regions of 
the body and can be life and organ threatening.1–3 Randomized controlled trials with 
standardized, physician-derived outcome measurement of disease activity and damage 
have revolutionized the treatment of these diseases.4–6 Systemic vasculitis is no longer 
invariably fatal, but patients can still suffer ongoing activity, organ damage that cannot 
be repaired, and adverse effects of immunosuppression.7–9
The impact of symptoms and side effects of treatment in systemic vasculitis can 
affect all aspects of health-related quality of life (HRQoL).8,10,11 Systemic vasculitis 
affects people of working age12 and those planning a family13,14 or active retirement.15 
Patients also face the situation of having a rare autoimmune rheumatic disease,16 which 
can be isolating, resulting in delays to get a diagnosis and treatment, and difficulties in 
navigating health care systems between different specialists.16 Patients with vasculitis 
rank items of importance (in terms of symptoms and impact), differently to how their 
clinicians would rank those items.17,18
The Outcome Measurement in Rheumatology (OMERACT) initiative is an interna-
tional collaboration of patients, researchers, clinicians, and methodologist to define core 
sets of outcome measurements for use in randomized controlled trials.19 Stakeholder 
groups including the Food and Drug Administration and pharmaceutical companies also 
participate.19 OMERACT has endorsed a core set of domains and outcome measures for 
use in clinical trials in ANCA-associated vasculitis (AAV)20, large-vessel vasculitis21, 
and Behçet’s syndrome,22 each set developed by the OMERACT Vasculitis Working 
Group. Measurement of disease activity levels and irreversible damage within clini-
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cal trials has been facilitated by physician-derived outcome 
measures, for example, the Vasculitis Damage Index.23 In 
recent years, the patient perspective in systemic vasculitis 
has been a major focus for the vasculitis research community. 
A new disease-specific patient-reported outcome (PRO), the 
AAV-PRO,24 has been validated; underpinning qualitative 
work in Takayasu’s arteritis (TAK) and Behcet’s syndrome 
has been performed;25,26 and evaluation of alternative generic 
PROs including the Patient-Reported Outcome Measurement 
Information System (PROMIS) is underway.27
Measurement of HRQoL in vasculitis has mostly relied 
on the use of “generic” PROs, mainly the Short Form 36 
(SF-36),28 which is a well-recognized and validated outcome 
measure that allows comparison between patients with sys-
temic vasculitis and other conditions.28 As generic PROs were 
not designed for use in a specific disease, these measures can 
have reduced face and content validity in some settings.29 
This lack of specificity may reduce the ability to detect dif-
ferences in disease states between patients and in the same 
patient over time.29 Trials in AAV, for example comparing 
cyclophosphamide to rituximab, have not demonstrated a dif-
ference in SF-36 scores between arms, despite differences in 
the toxicities of the medications.30 This may be due to a lack 
of sensitivity of the SF-36 or the high levels of glucocorticoids 
used in both trial arms. In a randomized trial of Avacopan (C5a 
receptor inhibitor) in AAV, patients not on glucocorticoids 
scored better on the physical domain of the SF-36.31
Disease-specific PROs should be developed with patient 
involvement throughout, in line with guidance from the US 
Food and Drug Administration on the development of PROs.32 
Good face and content validity is ensured by incorporating 
qualitative research with patients with the disease in question, 
to identify the full range of impacts of the disease and its 
treatment.33 Questionnaire items are then based on the themes 
identified and are refined through piloting and cognitive inter-
views.34 A survey including exploratory factor analysis35 and 
Rasch analysis36 can be used to identify the final structure of 
the PRO and to validate its measurement properties.24,37
This article describes the impact on HRQoL of living 
with AAV, TAK, giant cell arteritis (GCA), and Behçet’s 
syndrome. Measurements of the patient perspective in the 
systemic vasculitides, through the complimentary use of 
generic and disease-specific and symptom-specific PROs, 
are also described.
AAV
AAV encompasses three multisystem diseases: granulo-
matosis with polyangiitis, microscopic polyangiitis, and 
eosinophilic granulomatosis with polyangiitis.38 The AAVs 
are multisystem disorders resulting in inflammation and dam-
age occurring in the kidneys, lungs, skin, ear nose and throat, 
eyes, and neurological system, and these manifestations can 
impact on HRQoL.2,10
Newly diagnosed patients with AAV have demonstrated 
impairments in HRQoL at entry into European Vasculitis 
Study Group trials39, the Wegener’s Granulomatosis Etaner-
cept Trial,41 and the French MAINRITSAN trial.42 Physical 
functioning scores are the most affected, particularly in those 
with neurological involvement and older ages. Patients with 
AAV also report high levels of fatigue and rank this aspect as 
being of greatest importance to their overall HRQoL.17,43 Sur-
vey data suggest that AAV-related fatigue is likely to be mul-
tifactorial and associated with pain, sleep disturbance, and 
higher levels of inflammation.44 More than 40% of patients 
with vasculitis report symptoms of anxiety, and one-quarter 
report symptoms of depression, as measured by the Hospital 
Anxiety and Depression Scale.9 Fifty in-depth qualitative 
interviews with patients with AAV-identified themes related 
to fear, anxiety, and stress in 70% of participants, while 50% 
of interviewees reported depression and 50% reported anger 
due to their disease or its treatment.10
Within the 2010 OMERACT core set for AAV, the 
OMERACT Vasculitis Group included the generic –SF-36 
as the outcome measure to capture HRQoL.20 They also 
identified the need for further work around capturing patient 
perspectives in AAV including exploration of alternative 
generic item banks and a disease-specific PRO.45
An international collaboration of patients and research-
ers from the United Kingdom, United States, and Canada 
formed a steering committee to oversee the development of 
a disease-specific PRO.45
Qualitative interviews with 50 patients with AAV from 
the three countries identified the following themes: symptom 
severity, and the impact of problems and limitations imposed 
by patients’ AAV and treatment, on their work; domestic 
roles; family and social interactions (including activities 
and interests outside the home) and psychological state.10 
Underpinning themes were then recast as candidate questions 
for the new disease-specific PRO, and these questions were 
reduced and refined via piloting and cognitive interviewing.24 
A large-scale survey was then used to determine the ideal 
structure of the PRO, including domains and items, and to 
validate its measurement properties.24 AAV-PRO domain 
scores distinguish between patients who self-report active 
disease vs disease in remission, has good construct validity, 
and is reliable and feasible to use.24 It has good face validity 
due to having four patient partners on the steering committee 
and involvement of patients at each stage.24
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The AAV-PRO questionnaire 29-item includes six sub-
scales/domains: “Organ-Specific Symptoms”, “Systemic 
Symptoms”, “Treatment Side Effects”, “Social and Emo-
tional Impact”, “Concerns about the Future”, and “Physical 
Function”. The domains provide a profile of the impact of 
AAV and its treatment on patients’ everyday life.24
Each domain is scored separately to provide a profile of 
the overall impact of the disease and its treatment on HRQoL. 
Certain domains may be of interest in specific contexts; for 
example, the treatment and adverse effects domain may be 
important within therapeutic drug trials, but it would be 
important to collect the range of domain scores to identify 
the full impact on patients HRQoL and symptoms. In future, 
summary component scores may be derived, but this approach 
needs further investigation.
The AAV-PRO survey identified that women scored 
higher (ie, worse) on all six subscales.24 Trends toward worse 
scores have been previously seen in female patients with 
AAV,40 and HRQoL is reduced in other chronic conditions.46,47 
Younger people with AAV (<65) scored higher (worse) on the 
Social and Emotional Impact subscale of the AAV-PRO; this 
is also seen in other chronic diseases.46,48 Younger age is a risk 
factor for fatigue and negative illness perceptions in AAV.49
The OMERACT Vasculitis Working Group gained 
endorsement by OMERACT for use of certain PROMIS 
domains and the AAV-PRO in clinical trials of vasculitis.50 
These instruments are complementary to each other. Both 
require further work to assess their validity in longitudinal 
settings, including their ability to discriminate between 
treatments of varying efficacy in the setting of a randomized 
controlled trial. Comparison of AAV-PRO domain scores with 
SF-36 domain scores in clinical studies of patients with AAV, 
to examine different aspects of construct validity, will also 
be an important validation step for the AAV-PRO.
GCA
GCA is caused by inflammation of the blood vessels around 
the head and neck, and elsewhere.51 GCA frequently presents 
with severe headache, jaw claudication, systemic features 
including flu-like symptoms, fevers, and weight-loss, and 
polymyalgia rheumatica (inflammatory pain and stiffness 
in the hips and shoulders).52 There is a risk of visual loss in 
20% of untreated cases52,53 and high-dose glucocorticoids 
are required to protect sight.54,55 Glucocorticoids alone 
have been the only treatment available, but patients can 
suffer adverse frequent adverse effects including hyperten-
sion, diabetes, osteoporosis, psychiatric disturbance, and 
change in appearance.56–59 A novel biologic medication, 
the interleukin-6-receptor inhibitor tocilizumab, appears to 
improve HRQoL at 1 year in patients with GCA;60 this find-
ing should be examined further but may be associated with 
the drug’s glucocorticoid-sparing effect. The impact of GCA 
on patients’ lives is due to a combination of symptoms (eg, 
visual disturbance, musculoskeletal symptoms and pain), 
adverse effects of glucocorticoids, and the disruption to 
normal life.15 Patients fear blindness, have concerns about 
delay in diagnosis,15 and rank losing sight in both eyes per-
manently’, “having intense or severe pain” and “feeling weak, 
tired or exhausted” as key domains of HRQoL.11 In patients 
with GCA, SF-36 scores do not correlate with visual loss or 
systemic complications, so generic PROs may be unable to 
differentiate between clinically important groups.61,62 The 
OMERACT Vasculitis Working Group has, therefore, iden-
tified the development of a disease-specific PRO for GCA 
within their research agenda.21,63
At OMERACT 2018, qualitative work from patients 
with GCA in the United Kingdom and Australia was pre-
sented and included the following salient themes: “Anxi-
eties around getting a diagnosis of GCA”, “Description 
of symptoms related to GCA and its treatment”, “Lack 
of bodily strength, stability and stamina; difficulties with 
completing daily tasks”, “Difficulties with participating 
in social activities, work and caring roles”, “Not feeling 
normal and impact on general perception of health”, and 
“Anxiety and fear of the future”.64 These themes could be 
developed further into candidate questionnaire items for 
a disease-specific PRO for GCA.
The PROMIS is a bank of items, which have been gener-
ated from disease-specific PRO measures in a range of dif-
ferent diseases (examples include osteoarthritis, cancer, or 
asthma), to create generic item banks for particular domains 
eg, physical or mental health. Items within the PROMIS 
domains of Fatigue and Physical Function have been tested 
in patients with GCA and were found to be feasible to use, 
scores correlating with relevant SF-36 domain scores; but 
further validation work is needed.27
TAK
TAK is a systemic inflammatory condition that affects the 
large arteries, specifically the aorta and its major branches 
and the pulmonary arteries.65 Symptoms can be systemic 
including weight loss, fever and fatigue, or due to vascular 
inflammation and occlusion, leading to pain, claudication and 
tissue loss.65 Patients with TAK are diagnosed early in life. 
Patients with TAK have physical limitations and high levels 
of anxiety and depression compared with healthy controls;66 
scores are comparable to those from patients with ankylosing 
spondylitis and rheumatoid arthritis.67 Younger patients and 
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those in remission have better HRQoL, while those requiring 
immunosuppression have worse HRQoL.7
The OMERACT Large Vessel Vasculitis Working Group 
identified the lack of a disease-specific PRO for TAK.68 Quali-
tative research was performed through individual interviews 
and focus groups with patients with TAK from the United 
States and Turkey.25 Salient themes identified included “Pain 
and Discomfort”, “Fatigue and Low Energy Levels”, and 
“Emotional Effects”, and these themes could underpin the 
development of a disease-specific PRO for TAK.25
Behçet’s syndrome
Behçet’s syndrome affects a spectrum of various veins and 
arteries of different sizes38; patients can therefore present 
with a range of symptoms.69 Oral and genital ulcers, nodular 
and papulopustular skin lesions, pan-uveitus, inflammatory 
arthritis and bowel disease, and a range of neurological dis-
orders can occur.69,70
Oral and genital ulcers, neurological and ophthalmo-
logical involvement, joint pain, female sex, and high disease 
activity are specifically associated with worse HRQoL in 
patients with Behçet’s syndrome; all patients have worse 
SF-36 scores compared with healthy controls.8,71 Sexual 
function can be impaired in men and women.72
A systematic review of outcome measures used in Behçet’s 
syndrome by the OMERACT Vasculitis Working Group 
revealed large variability in terms of outcomes, including PROs 
used across trials.73 Generic measures to evaluate HRQOL in 
Behçet’s syndrome include the EQ-5D,73 but mainly the SF-36,74. 
Symptom-specific PROs have also been used in Behçet’s syn-
drome, including the Oral Health and Related Quality of Life 
Scale75 and the Arizona Sexual Experience Scale.72 Psycho-
logical impact has most commonly been measured using Beck 
Anxiety Scale76,77 and the Beck Depression Index.78
The review identified a validated disease-specific PRO, 
the Behçet’s Disease Quality of Life Scale (BD-QoL),37,77,79,80 
which was developed in the United Kingdom and has under-
gone cross-cultural adaptation and validation in Korean and 
Arabic.79,81 Item development was based on the qualitative 
work with patients with BD and included the following salient 
themes: “Relationships”, “Emotions”, “Limitations in Day 
to Day Activities”, and “Self-Image”.37
Conclusion
Patients with systemic vasculitides have different perspec-
tives on their disease and its impact to their clinicians. It is 
important to capture the patient perspective accurately and 
reliably within clinical studies using validated outcome mea-
sures, which assess areas of greatest importance to patients. 
A limitation of PROs is that some aspects of a condition, 
which are objectively important to measure and very relevant 
to outcome (eg, blood pressure), may not be experienced by 
patients and therefore not represented. PROs are, therefore, 
complementary to physician-derived outcomes in terms of 
determining what matters most to patients with vasculitis, in 
relation to their disease and its treatment. Greater precision 
when measuring the impact on patients, for example, in terms 
adverse effects and fatigue, will facilitate targeted assess-
ment of novel pharmacological and non-pharmacological 
interventions. There are advantages of using generic PROs, 
such as the SF-36, which facilitates direct comparison across 
diseases and, in some contexts, allows for unforeseen side 
effects to be detected; and the disease-specific PROs, such as 
the BD-QoL, which has fine-tuned, specific elements, with 
high face validity to patients with the disease in question. 
There is, therefore, a role for both.
The growing recognition of the importance of PROs in 
the assessment of vasculitis, and the availability of validated 
instruments to capture PROs in vasculitis may also mean that 
patients’ perspectives will be incorporated into composite 
outcome measures in future trials.
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